Pulmonary Arterial Hypertension News and Research RSS Feed - Pulmonary Arterial Hypertension News and Research

Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Elevated endothelial progenitor cells may characterise PAH patients

Elevated endothelial progenitor cells may characterise PAH patients

Plasma levels of endothelial progenitor cells are elevated in patients with pulmonary arterial hypertension, say researchers. [More]
Pulmonary hypertension impacts walking ability in SSc patients

Pulmonary hypertension impacts walking ability in SSc patients

The results of a meta-analysis show the adverse impact pulmonary hypertension has on the walking stamina of patients with systemic sclerosis. [More]

More evidence for combination therapy benefits in PAH

Another meta-analysis adds to evidence of increased benefits for patients with pulmonary arterial hypertension who are given combination therapy. [More]
Detailed digital models of human organs could bring substantial benefits to clinical trials

Detailed digital models of human organs could bring substantial benefits to clinical trials

Computer simulations of disease processes and detailed digital models of our organs could provide more accurate monitoring and outcome measurements for clinical trials, according to research being presented in Sheffield today. [More]
Novel gene therapy can treat pulmonary hypertension linked with heart failure

Novel gene therapy can treat pulmonary hypertension linked with heart failure

Scientists have used a novel gene therapy to halt the progression of pulmonary hypertension, a form of high blood pressure in the lung blood vessels that is linked to heart failure, according to a study led by Roger J. Hajjar, MD, Professor of Medicine and Director of the Cardiovascular Research Center at the Icahn School of Medicine at Mount Sinai. [More]
Meta-analysis supports combination therapy for PAH patients

Meta-analysis supports combination therapy for PAH patients

A meta-analysis shows that clinical worsening is significantly less likely in patients with pulmonary arterial hypertension if they are given combination treatment, rather than monotherapy. [More]
Minimally important dyspnoea, fatigue changes in PAH patients defined

Minimally important dyspnoea, fatigue changes in PAH patients defined

Researchers say that a change of around 1 unit in Borg dyspnoea or fatigue scores signifies an important change in patients with pulmonary arterial hypertension. [More]
Increased BMP7 levels predict PAH mortality

Increased BMP7 levels predict PAH mortality

Elevated levels of circulating bone morphogenetic protein 7 are associated with an increased mortality risk in patients with pulmonary arterial hypertension, find Chinese researchers. [More]
BMPR2 mutations affect outcomes of PAH patients

BMPR2 mutations affect outcomes of PAH patients

Mutations in the bone morphogenetic protein receptor type II gene affect not only the risk of developing pulmonary arterial hypertension but also the severity and outcomes of the disease, shows a meta-analysis of individual patient data. [More]
Tricuspid regurgitation tied to outcomes in PAH patients

Tricuspid regurgitation tied to outcomes in PAH patients

Tricuspid regurgitation progresses in line with right ventricular remodelling and increasing pulmonary artery systolic pressure in patients with pulmonary arterial hypertension, research shows. [More]
Regulatory immune cells compromised in PAH

Regulatory immune cells compromised in PAH

Research suggests that regulatory T cells may play a part in all subtypes of pulmonary arterial hypertension. [More]
PAH role proposed for left heart failure biomarker

PAH role proposed for left heart failure biomarker

Levels of galectin-3 are elevated in patients with pulmonary arterial hypertension and correlate with disease severity, research shows. [More]
Left ventricular tissue phase mapping predicts PAH outcomes

Left ventricular tissue phase mapping predicts PAH outcomes

A tissue phase mapping study shows that left ventricular function is abnormal in patients with pulmonary arterial hypertension and is linked to clinical outcomes. [More]
Ambrisentan avoids sildenafil drug interaction in PAH patients

Ambrisentan avoids sildenafil drug interaction in PAH patients

Sildenafil may be better given to pulmonary arterial hypertension patients in combination with ambrisentan than with bosentan, study findings suggest. [More]
BMPR2 mutations affect outcomes of PAH patients

BMPR2 mutations affect outcomes of PAH patients

Mutations in the bone morphogenetic protein receptor type II gene affect not only the risk of developing pulmonary arterial hypertension but also the severity and outcomes of the disease, shows a meta-analysis of individual patient data. [More]

Arrhythmias worth treating in PAH patients

Supraventricular arrhythmias are common in patients with pulmonary arterial hypertension but can be successfully managed with standard treatments, a study shows. [More]
Selexipag reduces clinical events in PAH patients

Selexipag reduces clinical events in PAH patients

Selexipag, alone or in combination with other classes of pulmonary arterial hypertension medication, reduced the composite rate of disease complications and deaths among patients in a phase III trial. [More]
New blood biomarkers could lead to better evaluation of treatment for patients with PAH

New blood biomarkers could lead to better evaluation of treatment for patients with PAH

New blood biomarkers reflecting vasoreactivity in lung blood vessels of patients with heart- and lung disease, can lead to simplified diagnostics and better evaluation of treatment for patients with the condition pulmonary arterial hypertension (PAH). [More]
Selexipag holds promise for treatment of pulmonary hypertension

Selexipag holds promise for treatment of pulmonary hypertension

Living with pulmonary arterial hypertension is challenging, but the chore of treating the rare heart disease may change following promising clinical trial data to be published in the Dec. 24 issue of the New England Journal of Medicine. [More]
Cardiome files NDS with Health Canada's TPD for approval of intravenous vernakalant

Cardiome files NDS with Health Canada's TPD for approval of intravenous vernakalant

Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the filing of a New Drug Submission (NDS) with Health Canada's Therapeutic Products Directorate (TPD) seeking Canadian approval of intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults with AF for up to 7 days. [More]
Advertisement